Literature DB >> 11818210

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

G Sava1, A Bergamo, S Zorzet, B Gava, C Casarsa, M Cocchietto, A Furlani, V Scarcia, B Serli, E Iengo, E Alessio, G Mestroni.   

Abstract

The influence of chemical stability on the antimetastatic ruthenium(III) compound imidazolium trans-imidazoletetrachlorodimethylsulphoxideruthenium(III) (NAMI-A) in aqueous solution was studied both in vitro and in vivo. The loss of dimethyl-sulphoxide (DMSO) ligand from the compound was tested by using a NAMI-A solution acidified with HCl at pH 3.0 and aged for 0, 4, 8 and 24 h prior to intraperitoneal (i.p.) injection into CBA mice bearing advanced MCa mammary carcinoma. The activity of NAMI-A on lung metastases showed no change even after the loss of DMSO ligand from up to 50% of the molecules. The reduction of NAMI-A did not modify the number of KB cells blocked in the S+G2M phases, independent of whether the reduction occurred outside the cells or after loading the cells with the compound prior to treatment with the reductants (ascorbic acid, glutathione or cysteine). In vivo, the complete reduction of NAMI-A with equivalent amounts of ascorbic acid, glutathione or cysteine prior to administration to mice bearing advanced MCa mammary carcinoma was more active than NAMI-A alone. The data show that NAMI-A, although undergoing a series of chemical modifications, maintains its antimetastatic activity in a broad range of experimental conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818210     DOI: 10.1016/s0959-8049(01)00389-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

Review 1.  New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

Authors:  Jan Reedijk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

Review 2.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

3.  A QM/MM study of the binding of RAPTA ligands to cathepsin B.

Authors:  Antonella Ciancetta; Samuel Genheden; Ulf Ryde
Journal:  J Comput Aided Mol Des       Date:  2011-06-24       Impact factor: 3.686

4.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

5.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

6.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

7.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

8.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

10.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.